{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"KarMMa-7","nct_id":"NCT04855136","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=karmma-7-nct04855136. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"KarMMa-7","arms":[{"description":"bb2121 will be administered at a target dose of 450 x 10\\^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.","label":"Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)","type":"EXPERIMENTAL"},{"description":"* bb2121 will be administered at a target dose of 450 x 10\\^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion\n* Enrollment is closed for this Arm","label":"Arm B- bb2121 in combination with BMS-986405 (JSMD194)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-04-25","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":21,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BB2121","otherNames":["ide-cel"],"type":"BIOLOGICAL"},{"name":"CC-220","otherNames":[],"type":"DRUG"},{"name":"BMS-986405","otherNames":["JSMD194"],"type":"DRUG"}],"last_update":"2026-07-09","lead_sponsor":"Celgene","official_title":"An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-04-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Does Limiting Toxicity (DLT) rates _Phase 1","timeFrame":"Up to 28 days from start of the combination therapy"},{"measure":"Complete Response Rate (CRR)_ Phase 2","timeFrame":"Up to 24 months"}],"references":[],"start_date":{"date":"2021-06-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04855136"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/karmma-7-nct04855136"}